<DOC>
	<DOC>NCT01985152</DOC>
	<brief_summary>The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan Trimethylethanolamine in healthy volunteers</brief_summary>
	<brief_title>A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy males or females Aged from 18 years to 45 years Body mass index (BMI) 19 to 25kg/m2 Has a known sensitivity to angiotensin II receptor blocker（ARB） With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor Has known or suspected history of alcoholism or drug abuse or misuse With a history of laboratory results that show the presence of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV) Pregnant,lactating，menstrual Vegetarian Postural hypotension Systolic blood pressure&lt;100mmHg，or&gt;130mmHg;and/or diastolic blood pressure&lt;70mmHg,or&gt;90mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>